Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Akums Drugs IPO is a book build issue of ₹1,856.74 crores. The issue is a combination of fresh issue of 1.00 crore shares aggregating to ₹680.99 crores and offer for sale of 1.73 crore shares aggregating to ₹1,175.75 crores.
Akums Drugs IPO bidding started from Jul 30, 2024 and ended on Aug 1, 2024. The allotment for Akums Drugs IPO was finalized on Aug 2, 2024. The shares got listed on BSE, NSE on Aug 6, 2024.
Akums Drugs IPO price band is set at ₹679.00 per share . The lot size for an application is 22. The minimum amount of investment required by an retail is ₹14,212 (22 shares). The lot size investment for sNII is 14 lots (308 shares), amounting to ₹2,09,132, and for bNII, it is 67 lots (1,474 shares), amounting to ₹10,00,846.
The issue includes a reservation of up to 2,43,902 shares for employees offered at a discount of ₹64.00 to the issue price.
ICICI Securities Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Akums Drugs IPO RHP for detailed Information.
| IPO Date | July 30, 2024 to August 1, 2024 |
| Listing Date | August 6, 2024 |
| Face Value | ₹2 per share |
| Issue Price Band | ₹646 to ₹679 per share |
| Issue Price Final | ₹679 per share |
| Lot Size | 22 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 2,73,68,143 shares (aggregating up to ₹1,856.74 Cr) |
| Fresh Issue | 1,00,37,708 shares (aggregating up to ₹680.99 Cr) |
| Offer for Sale | 1,73,30,435 shares of ₹2 (aggregating up to ₹1,175.75 Cr) |
| Employee Discount | ₹64.00 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 14,73,56,280 shares |
| Share Holding Post Issue | 15,73,71,007 shares |
Akums Drugs and Pharmaceuticals IPO offers total 2,73,68,151 shares. Out of which 2,03,43,188 (74.33%) allocated to QIB, 81,37,276 (29.73%) allocated to QIB, 40,68,637 (14.87%) allocated to NII, 27,12,424 (9.91%) allocated to RII and 1,22,05,912 (44.60%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 2,03,43,188 (74.33%) | NA |
| − Anchor Investor Shares Offered | 1,22,05,912 (44.60%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 81,37,276 (29.73%) | NA |
| NII (HNI) Shares Offered | 40,68,637 (14.87%) | NA |
| − bNII > ₹10L | 27,12,425 (9.91%) | 8,806 |
| − sNII < ₹10L | 13,56,212 (4.96%) | 4,403 |
| Retail Shares Offered | 27,12,424 (9.91%) | 1,23,292 |
| Employee Shares Offered | 2,43,902 (0.89%) | NA |
| Total Shares Offered | 2,73,68,151 (100.00%) |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Akums Drugs IPO raises ₹828.78 crore from anchor investors. Akums Drugs IPO Anchor bid date is July 29, 2024. Akums Drugs IPO Anchor Investors list
| Bid Date | July 29, 2024 |
| Shares Offered | 1,22,05,912 |
| Anchor Portion Size (In Cr.) | 828.78 |
| Anchor lock-in period end date for 50% shares (30 Days) | September 1, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | October 31, 2024 |
Akums Drugs IPO opens on July 30, 2024, and closes on August 1, 2024.
| IPO Open Date | Tue, Jul 30, 2024 |
| IPO Close Date | Thu, Aug 1, 2024 |
| Tentative Allotment | Fri, Aug 2, 2024 |
| Initiation of Refunds | Mon, Aug 5, 2024 |
| Credit of Shares to Demat | Mon, Aug 5, 2024 |
| Tentative Listing Date | Tue, Aug 6, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Aug 1, 2024 |
Investors can bid for a minimum of 22 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 22 | ₹14,938 |
| Retail (Max) | 13 | 286 | ₹1,94,194 |
| S-HNI (Min) | 14 | 308 | ₹2,09,132 |
| S-HNI (Max) | 66 | 1,452 | ₹9,85,908 |
| B-HNI (Min) | 67 | 1,474 | ₹10,00,846 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.
The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).
The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
Akums Drugs and Pharmaceuticals Limited's revenue increased by 13.81% and profit after tax (PAT) dropped by -99.19% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.50 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore | |||
| KPI | Values |
|---|---|
| ROE | 0.11% |
| ROCE | 3.37% |
| Debt/Equity | 0.69 |
| RoNW | -0.57 |
| PAT Margin | 0.02% |
| Price to Book Value | 13.69 |
The Company proposes to utilize the Net Proceeds towards the funding of the following objects:
[Dilip Davda] The company is enjoying a leadership in CDMO segment and has many blue-chip domestic as well as global pharma companies as its loyal customers. If we consider the restated performance excluding put call liabilities, the IPO is priced at a P/E of 29.79 based on FY24 earnings. The issue appears fully priced. Investors may park funds for the medium to long term. Read detail review...
| Listing Date | August 6, 2024 |
| BSE Script Code | 544222 |
| NSE Symbol | AKUMS |
| ISIN | INE09XN01023 |
| Final Issue Price | ₹679 per share |
| BSE Listing Group | B |
Akums Drugs & Pharmaceuticals Ltd.
304, Mohan Place,
LSC Saraswati Vihar,
Delhi - 110 034
Delhi, New Delhi
Phone: +91 11 6904 1000
Email: cs@akums.net
Website: http://www.akums.in/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: akumsdrugs.ipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Akums Drugs IPO is a main-board IPO of 2,73,68,143 equity shares of the face value of ₹2 aggregating up to ₹1,856.74 Crores. The issue is priced at ₹679 per share. The minimum order quantity is 22.
The IPO opens on July 30, 2024, and closes on August 1, 2024.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Akums Drugs IPO using UPI as a payment gateway. Zerodha customers can apply in Akums Drugs IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Akums Drugs IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Akums Drugs IPO opens on July 30, 2024 and closes on August 1, 2024.
Akums Drugs IPO lot size is 22, and the minimum amount required for application is ₹14,938.
You can apply in Akums Drugs IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Akums Drugs IPO will be done on Friday, August 2, 2024, and the allotted shares will be credited to your demat account by Monday, August 5, 2024. Check the Akums Drugs IPO allotment status.
The Akums Drugs IPO listing date is on Tuesday, August 6, 2024.
Useful Articles
RHP